NASDAQ: FPRX       Five Prime Thera Cmn
Last Price Today's Change   Day's Range   Trading Volume
34.52   +0.46 (1.35%)  34.15 - 35.13  296,887


Avg Volume (4 weeks):0
4 Weeks Range:31.79 - 37.24
52 Weeks Range:31.79 - 60.98
Average Price Target:-


No recent Headlines for this stock.

Business Background

Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company's product candidates include Cabiralizumab (FPA008), which is an antibody that inhibits colony stimulating factor-1 receptor, that it is studying in clinical trials as a monotherapy in pigmented villonodular synovitis, and in multiple cancers in combination with programmed-death 1 immune checkpoint inhibitor, Opdivo; FPA144, which is an antibody that inhibits fibroblast growth factor receptor 2b, that it is initially developing to treat patients with gastric (stomach) cancer and is in a Phase I clinical trial, and FP-1039, which is a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors, involved in cancer cell proliferation and new blood vessel formation and is in Phase Ib clinical development to treat patients with malignant pleural mesothelioma. Its preclinical programs include FPA150, FPA154 and FPT155.

  Be the first to like this.


4418  2693  561  651 

Top 10 Active Counters
 BAC 24.226+0.596 
 JNUG 4.32-0.93 
 BABY 40.95+0.35 
 AKS 6.47-0.65 
 NUGT 8.005-1.355 
 SPY 238.73+1.56 
 GDX 22.075-1.125 
 ABX 17.02-2.02 
 FCX 12.895+0.665 
 XLF 23.95+0.27 
Partners & Brokers